Previous close | 1.0300 |
Open | 1.0600 |
Bid | 1.0000 x 1400 |
Ask | 1.0800 x 3100 |
Day's range | 1.0000 - 1.1009 |
52-week range | 0.9400 - 9.7000 |
Volume | |
Avg. volume | 1,810,555 |
Market cap | 90.6M |
Beta (5Y monthly) | 0.21 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Specalty medical-device maker PAVmed (NASDAQ: PAVM) didn't make for a great stock on Wednesday. PAVmed filed a shelf-registration statement with the Securities and Exchange Commission earlier in the day. In PAVmed's case, it's aiming to float $275 million worth of one or more of: common stock, preferred stock, warrants, debt securities, and units (i.e., a combination of at least two of the preceding types of securities).
Thursday was another great day for the stock market, although the Nasdaq Composite (NASDAQINDEX: ^IXIC) lagged behind some other major market benchmarks. Small-cap stocks don't always get as much attention as their larger counterparts, but they often have the best growth prospects. On Thursday morning, shares of Veritone (NASDAQ: VERI) and PAVmed (NASDAQ: PAVM) were among the top performers on the Nasdaq.
What happened Shares of PAVmed (NASDAQ: PAVM), a maker of tools for early detection of esophageal and pancreatic cancer, were down more than 15% as of 11:35 a.m. EDT today after the company reported earnings yesterday afternoon.